A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies
Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
|3||Active, not recruiting||
Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
|4||Active, not recruiting||
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
† Study has passed its completion date and status has not been verified in more than two years.